The A61G EGF polymorphism is associated with development of extraaxial nervous system tumors but not with overall survival

Cancer Genetics and Cytogenetics

Volumn 198, Issue 1, 2010, Pages 15-21

  Oliveira de Almeida, Luciana ^a   Custódio, Aline Cadurin ^a   José dos Santos, Marcelo ^b   Almeida, José R W ^b   Clara, Carlos Afonso ^b   Pinto, Giovanny Rebouças ^c   Rey, Juan A ^d   Casartelli, Cacilda ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Barretos Cancer Hospital Pio XII Foundation   (Brazil)

^c FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPIDERMAL GROWTH FACTOR; GLYCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; BRAZIL; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; METASTASIS; NEURILEMOMA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR GROWTH; GENETICS; MIDDLE AGED; MORTALITY; NERVOUS SYSTEM TUMOR;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MENINGIOMA; MIDDLE AGED; NERVOUS SYSTEM NEOPLASMS; NEURILEMMOMA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950346718     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.11.013     Document Type: Article

References (29)

1. Samii M., Gerganov V.M. Surgery of extra-axial tumors of the cerebral base. Neurosurgery 2008, 62(6 Suppl 3):1153-1166.
2. Liu Y., Pang J.C., Dong S., Mao B., Poon W.S., Ng H.K. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 2005, 36:416-425.
3. Bondy M., Ligon B.L. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996, 29:197-205.
4. Welling D.B., Guida M., Goll F., Pearl D.K., Glasscock M.E., Pappas D.G., Linthicum F.H., Rogers D., Prior T.W. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 1996, 98:189-193.
5. Drevelegas A. Extra-axial brain tumors. Eur Radiol 2005, 15:453-467.
6. Posner J., Chernik N. Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579-592.
7. Maroldi R., Ambrosi C., Farina D. Metastatic disease of the brain: extra-axial metastases (skull, dura, leptomeningeal) and tumour spread. Eur Radiol 2005, 15:617-626.
8. Goustin A.S., Leof E.B., Shipley G.D., Moses H.L. Growth factors and cancer. Cancer Res 1986, 46:1015-1029.
9. Araújo A.P., Ribeiro R., Pinto D., Pereira D., Sousa B., Mauricio J., Lopes C., Medeiros R. Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease. DNA Cell Biol 2009, 28:265-269.
10. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009, 122:1-8.
11. Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H., Higashiyama S., Neuroglycan C. a novel member of the neuregulin family. Biochem Biophys Res Commun 2004, 321:1045-1049.
12. Harari P.M., Allen G.W., Bonner J.A. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007, 25:4057-4065.
13. Normanno N., Bianco C., De Luca A., Salomon D.S. The role of EGF-related peptides in tumor growth. Front Biosci 2001, 6:D685-D707.
14. Fisher D.A., Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990, 11:418-442.
15. Puttonen S., Keltikangas-Järvinen I., Elovainio M., Kivimäi M., Rontu R., Lehtimäki T. Temperamental activity and epidermal growth factor A61 G polymorphism in Finnish adults. Neuropsychobiology 2007, 56:208-212.
16. Lazar L.M., Blum M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-α mRNA in mouse brain by a quantitative nuclease protection assay. J Neurosci 1992, 12:1688-1697.
17. Parkin D.M., Wabinga H., Nambooze S. Completeness in an African cancer registry. Cancer Causes Control 2001, 12:147-152.
18. Kang S., Kim J., Park N.H., Song Y.S., Park S.Y., Kang S.B., Lee H.P. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007, 17:492-496.
19. Shahbazi M., Pravica V., Nasreen N., Fakhoury H., Fryer A.A., Strange R.C., Hutchinson P.E., Osborne J.E., Lear J.T., Smith A.G., Hutchinson I.V. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002, 359:397-401.
20. Cui L., Pan X.M., Ma C.F., Shang-Guan J., Yu H.B., Chen G.X., Wang J. Association between epidermal growth factor polymorphism and esophageal squamous cell carcinoma susceptibility. Dig Dis Sci 2009 Jan. 27, [Epub ahead of print; doi:10.1007/s10620-008-0700-5].
21. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006, 18:2089-2097.
22. Vauleon E., Auger N., Benouaich-Amiel A., Laigle-Donadey F., Kaloshi G., Lejeune J., Delattre J.Y., Thillet J., Sanson M. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet 2007, 172:33-37.
23. Costa B.M., Ferreira P., Costa S., Canedo P., Oliveira P., Silva A., Pardal F., Suriano G., Machado J.C., Lopes J.M., Reis R.M. Association between functional EGF + 61 polymorphism and glioma risk. Clin Cancer Res 2007, 13:2621-2626.
24. Spindler K.L., Nielsen J.N., Ornskov D., Brandslund I., Jakobsen A. Epidermal growth factor (EGF) A61 G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol 2007, 46:1113-1117.
25. Wu G.Y., Hasenberg T., Magdeburg R., Bönninghoff R., Sturm J.W., Keese M. Association between EGF, TGF-β1, VEGF gene polymorphism and colorectal cancer. World J Surg 2009, 33:124-129.
26. Tanabe K.K., Lemoine A., Finkelstein D.M., Kawasaki H., Fujii T., Chung R.T., Lauwers G.Y., Kulu Y., Muzikansky A., Kuruppu D., Lanuti M., Goodwin J.M., Azoulay D., Fuchs B.C. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008, 299:53-60.
27. Teixeira A.L., Ribeiro R., Cardoso D., Pinto D., Lobo F., Fraga A., Pina F., Calais-da-Silva F., Medeiros R. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 2008, 14:3367-3371.
28. Och W., Mariak Z., Smółka M., Badowski J., Koziorowski M. Epidermal growth factor expression in brain neoplasms [In Polish]. Neurol Neurochir Pol 2000, 34:1165-1172.
29. Vishnoi M., Pandey S.N., Modi D.R., Kumar A., Mittal B. Genetic susceptibility of epidermal growth factor β1 509C>T gene polymorphisms with gallbladder cancer. Hum Immunol 2008, 69:360-367.